Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “hold” rating reaffirmed by stock analysts at Cowen and Company in a report issued on Friday.

The analysts wrote, “Pacira Pharmaceuticals Receives a Hold from Cowen & Co. | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=e20e19e287&wpp_id=456309’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Pacira Pharmaceuticals Receives a Hold from Cowen & Co.”

Several other research firms also recently commented on PCRX. Jefferies Group reiterated a “buy” rating and set a $60.00 target price (down from $74.00) on shares of Pacira Pharmaceuticals in a research report on Monday, September 26th. BMO Capital Markets restated a “sell” rating and issued a $36.00 price target on shares of Pacira Pharmaceuticals in a research report on Tuesday, July 19th. Brean Capital initiated coverage on shares of Pacira Pharmaceuticals in a research report on Friday, October 7th. They issued a “hold” rating on the stock. Mizuho restated a “buy” rating on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 22nd. Finally, Wedbush restated an “outperform” rating and issued a $105.00 price target (down previously from $109.00) on shares of Pacira Pharmaceuticals in a research report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $72.83.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 1.05% during midday trading on Friday, hitting $32.90. 253,906 shares of the company traded hands. The stock’s 50-day moving average is $37.91 and its 200-day moving average is $43.74. Pacira Pharmaceuticals has a 12-month low of $31.08 and a 12-month high of $80.25. The firm’s market capitalization is $1.23 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Thursday, August 4th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.03 by $0.16. Pacira Pharmaceuticals had a negative net margin of 4.21% and a positive return on equity of 0.02%. The business had revenue of $69.60 million for the quarter, compared to the consensus estimate of $67.80 million. During the same period last year, the company earned $0.20 EPS. The firm’s revenue was up 17.8% compared to the same quarter last year. Analysts anticipate that Pacira Pharmaceuticals will post $0.44 EPS for the current fiscal year.

In other news, CEO David M. Stack sold 15,000 shares of the company’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $45.32, for a total value of $679,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President James S. Scibetta sold 25,000 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $45.21, for a total transaction of $1,130,250.00. The disclosure for this sale can be found here. Company insiders own 6.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. FMR LLC raised its stake in Pacira Pharmaceuticals by 19.1% in the second quarter. FMR LLC now owns 5,567,088 shares of the company’s stock valued at $187,778,000 after buying an additional 892,511 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in Pacira Pharmaceuticals by 92.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,333,868 shares of the company’s stock valued at $44,991,000 after buying an additional 640,814 shares during the last quarter. Schroder Investment Management Group purchased a new stake in Pacira Pharmaceuticals during the second quarter valued at about $16,163,000. Point72 Asset Management L.P. purchased a new stake in Pacira Pharmaceuticals during the second quarter valued at about $9,486,000. Finally, EverPoint Asset Management LLC purchased a new stake in Pacira Pharmaceuticals during the second quarter valued at about $8,938,000.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.